RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

560

Participants

Timeline

Start Date

May 2, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Obstructive Sleep Apnea
Interventions
DRUG

IHL-42X Low Dose

Softgel capsule

DRUG

IHL-42X High Dose

Softgel capsule

DRUG

Placebo

Softgel capsule

DRUG

IHL-42X (Optimal Dose)

Softgel capsule

DRUG

Dronabinol

Softgel capsule

DRUG

Acetazolamide

Softgel capsule

DRUG

Placebo

Softgel capsule

Trial Locations (20)

20854

Meridian Clinical Research, LLC, Rockville

28078

Advanced Respiratory and Sleep Medicine, PLLC, Huntersville

29615

Velocity Clinical Research - Greenville, Greenville

29621

Velocity Clinical Research - Anderson, Anderson

30328

NeuroTrials Research, Inc., Atlanta

32256

Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Jacksonville), Jacksonville

32806

Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Orlando), Orlando

38119

Clinical Neuroscience Solutions, Inc. (CNS Healthcare of Memphis), Memphis

45212

CTI Clinical Trial and Consulting Services, Cincinnati

70072

Tandem Clinical Research, LLC, Marrero

78731

FutureSearch Trials, Austin

90806

CenExel CNS- Los Alamitos, Long Beach

91910

Exalt Clinical Research, Chula Vista

91786-4985

Pacific Clinical Research Medical Group, Upland

33596-8262

Teradan Clinical Trials, Valrico

33409-3401

Palm Beach Research Center, West Palm Beach

21075-6434

Centennial Medical Group, Elkridge

89052-5016

Henderson Clinical Trials,LLC, Henderson

45245-4501

Intrepid Research, Cincinnati

75231-3442

FutureSearch Trials of Dallas, LP, Dallas

Sponsors
All Listed Sponsors
lead

Incannex Healthcare Ltd

INDUSTRY

NCT06146101 - RePOSA-Revealing the Efficacy of IHL-42X Use in Patients With OSA | Biotech Hunter | Biotech Hunter